Bristol-Myers Squibb Co. (BMY): Price and Financial Metrics

BMY POWR Grades

• BMY scores best on the Value dimension, with a Value rank ahead of 96.63% of US stocks.
• BMY's strongest trending metric is Quality; it's been moving down over the last 177 days.
• BMY ranks lowest in Momentum; there it ranks in the 3rd percentile.

BMY Stock Summary

• With a market capitalization of $149,788,149,334, BRISTOL MYERS SQUIBB CO has a greater market value than 98.97% of US stocks.
• BRISTOL MYERS SQUIBB CO's stock had its IPO on January 1, 1986, making it an older stock than 93.22% of US equities in our set.
• Over the past twelve months, BMY has reported earnings growth of -284.97%, putting it ahead of just 5.95% of US stocks in our set.
• If you're looking for stocks that are quantitatively similar to BRISTOL MYERS SQUIBB CO, a group of peers worth examining would be TXN, NVS, AMGN, SNY, and CSCO.
• Visit BMY's SEC page to see the company's official filings. To visit the company's web site, go to www.bms.com.

BMY Valuation Summary

• In comparison to the median Healthcare stock, BMY's price/earnings ratio is 16.33% higher, now standing at 22.8.
• BMY's EV/EBIT ratio has moved down 27.4 over the prior 243 months.

Below are key valuation metrics over time for BMY.

BMY Growth Metrics

Its year over year net cashflow from operations growth rate is now at 15.83%.
• The 5 year net income to common stockholders growth rate now stands at -71.66%.
• The year over year net income to common stockholders growth rate now stands at 200.51%.

BMY's revenue has moved up $26,104,000,000 over the prior 52 months.

The table below shows BMY's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-06-30	47,144	15,396	6,617
2022-03-31	46,960	16,195	6,251
2021-12-31	46,385	16,207	6,994
2021-09-30	45,468	15,820	-5,405
2021-06-30	44,384	12,773	-5,079
2021-03-31	42,810	13,982	-6,219

BMY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• BMY has a Quality Grade of B, ranking ahead of 79.64% of graded US stocks.
• BMY's asset turnover comes in at 0.38 -- ranking 124th of 680 Pharmaceutical Products stocks.
• PAHC, ACUR, and XLRN are the stocks whose asset turnover ratios are most correlated with BMY.

The table below shows BMY's key quality metrics over time.